CAJ | 학술논문

目的：系统评价荧光膀胱镜引导经尿道膀胱肿瘤切除术（transurethral resection of bladder tumor，TUR －bt）治疗非肌层浸润性膀胱癌（nonmuscle invasive bladder cancer，NMIBC）的疗效。方法在国内外数据库中，检索15 a 内对比荧光膀胱镜和比普通膀胱镜辅助 TUR －BT 术疗效的随机对照研究（randomized controlled trial，RCT）。按纳入和排除标准选择文献、提取资料；采用 RevMan5．2软件进行荟萃分析。结果共纳入15篇随机对照试验，共2718例患者。分析结果显示，荧光膀胱镜辅助 TUR －bt 术治疗 NMIBC 后，肿瘤1年复发率（RR ＝0．71，95％ CI 0．58～0．87）、2年复发率（RR ＝0．60，95％ CI 0．50～0．73）差异均有统计学意义；术后远期肿瘤进展率（RR ＝0．81，95％ CI 0．62～1．13）差异无统计学意义。结论荧光膀胱镜引导 TUR －bt 可降低肿瘤复发率，但不能降低其进展为肌层浸润性膀胱癌的发生率。
목적：계통평개형광방광경인도경뇨도방광종류절제술（transurethral resection of bladder tumor，TUR －bt）치료비기층침윤성방광암（nonmuscle invasive bladder cancer，NMIBC）적료효。방법재국내외수거고중，검색15 a 내대비형광방광경화비보통방광경보조 TUR －BT 술료효적수궤대조연구（randomized controlled trial，RCT）。안납입화배제표준선택문헌、제취자료；채용 RevMan5．2연건진행회췌분석。결과공납입15편수궤대조시험，공2718례환자。분석결과현시，형광방광경보조 TUR －bt 술치료 NMIBC 후，종류1년복발솔（RR ＝0．71，95％ CI 0．58～0．87）、2년복발솔（RR ＝0．60，95％ CI 0．50～0．73）차이균유통계학의의；술후원기종류진전솔（RR ＝0．81，95％ CI 0．62～1．13）차이무통계학의의。결론형광방광경인도 TUR －bt 가강저종류복발솔，단불능강저기진전위기층침윤성방광암적발생솔。
Objective To evaluate the outcome of fluorescence cystoscopy -guided transurethral resection of bladder tumor in the treatment of non -muscle invasive bladder cancer.Methods The 15 years’randomized controlled trials on fluorescence cystoscopy versus conventional cystoscopy -guided TUR -bt in the domestic and international databases were reviewed,materials were selected according to inclusion and exclusion criterias and informations were extracted.RevMan 5.2 software was used to conduct a meta -analysis.Results A total of 15 randomized controlled trials,a total of 2 718 cases of patients were included. 1 and 2 -year recurrence rates of fluorescence cystoscopy -guided TUR -bt treatment group were 0.71 (RR =0.71,95% CI 0.58 ~0.87)and 0.60 (RR =0.60,95% CI 0.50 ~0.73 ),and the difference was statistically significant.But long -term postoperative tumor progression rate (RR =0.81,95% CI 0.62 ~1.13)was not statistically different.Conclusion The fluores-cence cystoscopy -guided TUR -bt can reduce the rate of tumor recurrence,but it does not reduce the incidence of progression to muscle invasive bladder cancer.